NF-κB-activated dendritic cells

This technology here describes an immune-therapeutic approach with dendritic cells (DC) for the treatment of cancer. It overcomes constraints of current DC therapy models like limited IL-12 production, a cytokine which is critical for immunologic memory. Therefore and most importantly, cytotoxic T cells induced by these designer DC combine a memory-like phenotype and a markedly increased secondary expandability with a high lytic capacity. Furthermore, this approach is by far more cost efficient than competing products.

Further information: PDF

Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0

Contact
Peer Biskup

As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.